Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comment on 'Incidence and Mortality of Mucous Membrane Pemphigoid in France': reply from authors.

The British journal of dermatology·2026

Same author

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026

Same author

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

The Journal of investigative dermatology·2026

Same author

Tocilizumab for severe and refractory mucous membrane pemphigoid.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

Same author

Incidence and Mortality of Mucous Membrane Pemphigoid in France.

The British journal of dermatology·2026

Same author

Baricitinib and low-dose prednisone for very severe alopecia areata: A retrospective case series.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

Same journal

Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy.

Immunotherapy·2026

Same journal

CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.

Immunotherapy·2026

Same journal

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026

Same journal

Exploring global research trends in sublingual immunotherapy of allergic rhinitis: a comprehensive bibliometric analysis.

Immunotherapy·2026

Same journal

Autoimmune encephalitis and axonal polyradiculoneuropathy following therapy with adalimumab and secukinumab: a case report and literature review.

Immunotherapy·2026

Same journal

Time-dependent prognostic impact of distant metastatic sites in small cell lung cancer: a comparative analysis of pre- and post-immunotherapy eras.

Immunotherapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Rituximab in pemphigus.

Vivien Hebert¹, Pascal Joly¹

¹Department of Dermatology, Rouen University Hospital, & INSERM U 1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.

|October 25, 2017

Summary

This summary is machine-generated.

Rituximab, a B-cell depleting therapy, shows promise in treating pemphigus, a severe autoimmune blistering disease. A recent trial indicates its first-line use with prednisone is more effective and safer than high-dose corticosteroids alone.

Keywords:

B lymphocytes CD20 anti-desmoglein antibodies autoimmune regimen corticosteroids efficacy pemphigus superficial pemphigus vulgaris rituximab safety

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Published on: April 9, 2019

Related Experiment Videos

Last Updated: Feb 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Published on: April 9, 2019

Area of Science:

Immunology
Dermatology
Autoimmune Diseases

Background:

Pemphigus is a severe autoimmune blistering disease characterized by autoantibodies against desmogleins, causing keratinocyte separation.
Rituximab targets CD-20 B-lymphocytes, reducing pathogenic autoantibodies and offering therapeutic potential in pemphigus.
Historically, rituximab was used off-label for refractory pemphigus or in patients intolerant to corticosteroids.

Purpose of the Study:

To evaluate the efficacy and safety of first-line rituximab combined with a short-term prednisone regimen in moderate to severe pemphigus.
To compare this novel regimen against the standard high-dose corticosteroid treatment.

Main Methods:

A large randomized clinical trial was conducted.
Participants with moderate to severe pemphigus were assigned to either rituximab plus short-term prednisone or high-dose corticosteroids.

Main Results:

The combination of rituximab and short-term prednisone demonstrated superior efficacy compared to the standard corticosteroid regimen.
This new therapeutic approach was also found to be potentially safer for patients with moderate to severe pemphigus.

Conclusions:

First-line treatment with rituximab and a limited course of prednisone is a highly effective and safer alternative for pemphigus management.
This regimen represents a significant advancement in treating moderate to severe pemphigus, potentially reducing long-term corticosteroid toxicity.